Author

S Wang

Observed names: Sa A Wang, Sa A. Wang, Shu-Hsien Wang, Shubing Wang, Shuqi Wang, Wang S-S

Institutions: The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, National Cheng Kung University Hospital, National Cheng Kung University

Observed institutions: The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Institut für Hämatopathologie Hamburg, National Cheng Kung University Hospital, National Cheng Kung University

ORCID: 0000-0001-9385-9911

Observed ORCIDs: 0000-0001-9385-9911, 0000-0002-0285-8778

OpenAlex ID: A5023925153

c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties

1995 · Wang S-S · Lung Cancer · 210

p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma

2005 · G Z Rassidakis, A Thomaides, et al. · Leukemia · 52

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial

2026 · Alexander D. Sherry, Cara Haymaker, et al. · Journal of Clinical Oncology · 7

Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density

2026 · Haochen Nan, Xinyuan Shen, et al. · Journal of Hematology & Oncology · 1

Amplification and Overexpression of Cyclin D1 in Epstein-Barr Virus–Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Targeted Next-Generation Sequencing Study

2026 · Ying-Ren Chen, Po-Min Chiang, et al. · Modern Pathology · 1

Genetic Profile, Treatment Response, and Outcomes of BCR::ABL1-Positive Mixed-Phenotype Acute Leukemia: A Study From the BCR::ABL1 Pathology Group

2026 · Qiudan Shen, Xiaoyan Huang, et al. · Modern Pathology · 1

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53 ‐Mutated Cases

2026 · Hong Fang, Joseph D. Khoury, et al. · American Journal of Hematology

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study

2026 · Nicholas J. Short, Alex Bataller, et al. · Journal of Hematology & Oncology

Acute myeloid leukemia with mast cell differentiation evolving into mast cell leukemia

2026 · Liangli Wang, Jie Xu, et al. · Cytometry Part B Clinical Cytometry

Clinicopathologic features of systemic ALK-negative anaplastic large cell lymphoma with TP53 deletion

2026 · Wei J Wang, Guilin Tang, et al. · American Journal of Clinical Pathology

Works count: 10

Citation count: 272

H-index: 3

I10-index: 2